Zanidatamab Zovodotin is a monoclonal antibody conjugated commercialized by Zymeworks, with a leading Phase I program in Adenocarcinoma Of The Gastroesophageal Junction. According to Globaldata, it is involved in 4 clinical trials, of which 1 is ongoing, and 3 are planned. GlobalData uses proprietary data and analytics to provide a complete picture of Zanidatamab Zovodotin’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.
Smarter leaders trust GlobalData
The revenue for Zanidatamab Zovodotin is expected to reach an annual total of $54 mn by 2040 in the US based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.
Zanidatamab Zovodotin Overview
Zanidatamab Zovodotin is under development for the treatment of HER-2 positive breast cancer, brain metastases, endometrial cancer, gastroesophageal adenocarcinoma, gynecologic cancers, metastatic breast cancer, non-small cell lung cancer, anal cancer, and colorectal cancer. It is being administered through intravenous route. It comprises Azymetric biparatopic anti-HER2 antibody conjugated to proprietary cytotoxic payload (auristatin) via a cleavable linker. The drug candidate is an bi-specific antibody-drug conjugate (biparatopic antibody) targeting tumor cells expressing ECD4 and ECD2 epitopes of HER2. It is developed based on Azymetric and Zymelink technology platforms. These technologies enables the production of ADCs with target affinity, effector function and increase in circulation half life. ZW49 delivers a novel auristatin (cell-killing compound) to tumor cells by taking advantage of the enhanced antibody-HER2 internalization of zanidatamab.
Zymeworks Overview
Zymeworks is a clinical-stage biotechnology company that develops novel and multifunctional biotherapeutics. It utilizes Azymetric, Zymelink, EFECT, Protect and T Cell Engagers technology platforms to develop drugs. The company’s pipeline products include zanidatamab, a bispecific antibody that targets two distinct domains of the human epidermal growth factor receptor 2 (HER2) that treats gastroesophageal adenocarcinomas, biliary tract, gastrointestinal and breast cancer; and zanidatamab zovodotin is a HER2-targeted bispecific antibody-drug conjugate (ADC) for expressing cancers. Its preclinical products include ZW191, ZW171, ZW251 and ZW220 targeting ovarian, endometrial and lung and liver cancers and hepatocellular carcinoma, among others. The company operates through its subsidiaries in the US, Ireland, Canada, the UK and Singapore. Zymeworks is headquartered in Vancouver, British Columbia, Canada.
The company reported revenues of (US Dollars) US$76 million for the fiscal year ended December 2023 (FY2023), a decrease of 81.6% over FY2022. The operating loss of the company was US$138.1 million in FY2023, compared to an operating profit of US$130.5 million in FY2022. The net loss of the company was US$118.7 million in FY2023, compared to a net profit of US$124.3 million in FY2022.
For a complete picture of Zanidatamab Zovodotin’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, drug margins and company expenses. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.
The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate valuation, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA) and phase transition success rate (PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.
